What no other preclinical system can do
In-vivo animal models lack human relevance and in-vitro cell culture models fail to recreate the complexity of human tissues, making it difficult to justify high-stakes decisions with confidence. Testing therapeutic responses in intact human tissue, not in models designed to approximate it, provides data that can be relied upon/used to make better decisions/more confident decisions.
Our proprietary tissue bioreactor sustains native 3D tissue architecture, active cellular signaling and intact disease phenotype across an extended study durations, without freezing or fixation. Designed to maintain viable, intact human tissue under controlled physiological conditions, our platform enables our experts to study therapeutic response in human disease for up to 10 days.
Stronger evidence for critical decisions
Conventional in-vitro models cannot fully replicate the complexity of human disease biology. FibroFind combines viable, intact human tissue with proprietary bioreactor technology to preserve fresh native tissue architecture and generate more human-relevant evidence.
Intact, viable human tissue sustained for up to 10 days
Enabling therapeutic response to be monitored beyond conventional short-term culture windows. Patented bioreactor technology sustains native tissue architecture and intact disease biology for up to 10 days, enabling therapeutic response to be tracked as it develops.
Exclusive to FibroFind
Patented. Protected. Exclusive. Our bioreactor technology is not licensed or used elsewhere.
Don't approximate human biology. Test it.
The extended culture duration provided by the bioreactor enables true induction and attenuation of disease, to improve understanding of the cellular and molecular drivers of disease, and to identify their mode of action..
The precision needed for complex pathophysiology
Our bioreactor operates alongside advanced liquid handling robotics and automation of data analysis, ensuring precision and reproducibility over all aspects of your studies.
For you, that means greater confidence when evaluating results, assessing compound performance and building a body of evidence that is reproducible, scalable and suitable for decision-making.
Human biology. Preserved.
Understand how our tissue bioreactor technology can support your program and strengthen your evidence base.
Applied across tissue types and disease areas
We utilize our bioreactor cultured precision cut tissue slices in studies across a range of chronic diseases.
Explore how liver, lung and kidney precision cut tissue slices can be used to evaluate mechanism, efficacy and therapeutic response directly in human tissue or disease, and how this can be applied to your program.
Related resources
Explore our insights to learn more about how data generated in viable, intact human tissue supports lead prioritization and reduces uncertainty in early development.
Poster
Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices
See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.
The evidence your program demands
Speak to our team about your program.